A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function

Clinical Transplantation

Volumn 14, Issue 6, 2000, Pages 550-554

  Chang, George J ^a   Mahanty, Harish D ^a   Vincenti, Flavio ^a   Freise, Chris E ^a   Roberts, John P ^a   Ascher, Nancy L ^a   Stock, Peter G ^a   Hirose, Ryutaro ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti CD25 mAb; Daclizumab; Delayed kidney function; Graft function; Immunosuppression; Kidney transplantation; Sirolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN; CORTICOSTEROID; CREATININE; ESTERASE INHIBITOR; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; THYMOCYTE ANTIBODY;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CADAVER KIDNEY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT SURVIVAL; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; ORGAN DONOR; POSTOPERATIVE CARE; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CALCINEURIN; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; RECEPTORS, INTERLEUKIN-2; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 0033652890     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2000.140606.x     Document Type: Article

References (16)

1. Delayed graft function does not reduce the survival of renal transplant allografts
2. Delayed graft function: Risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation
3. Delayed graft function: Risk factors and implications for renal allograft survival
4. Delayed graft function after renal transplantation
5. The high cost of delayed graft function in cadaveric renal transplantation
6. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis
7. The impact of the quality of initial graft function on cadaver kidney transplants
8. Immunologic and non-immunologic factors: Different risks for cadaver and living donor transplantation
9. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine sirolimus European renal transplant study group
10. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation daclizumab triple therapy study group
11. Can antibody prophylaxis allow sparing of other immunosuppressives?
12. One or Two Doses of Daclizumab Provide Effective Immunosuppression for
13. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
14. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity
15. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression